Formulations for reducing neuronal degeneration
AssigneeUniversity of Massachusetts
InventorsThomas B. SHEA, Robert J. NICOLOSI, Eugene ROGERS
Life of this patent
Estimating the term…
Abstract
Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).
Claims20
A method for treating a neurodegenerative disorder in a mammal, the method comprising administering to the mammal an amount of a formulation effective to reduce a level of reactive oxygen species (ROS) in an in vitro neural cell culture, wherein the formulation comprises, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms.
A composition comprising, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition reduces a level of reactive oxygen species (ROS) in an in vitro neural cell culture.
8-25. (canceled)
A composition comprising folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition improves memory in a subject.
Dependencies are inferred from the claim text.